source
- Supernus and Indivior merge to form CNS-focused company with 11 marketed drugs and $2.2B revenue targetSupernus Pharmaceuticals and Indivior Pharmaceuticals announced an all‑stock merger of equals, creating a central nervous system‑focused company that will combine their product lines and operations…
- Wall Street reacts negatively to AstraZeneca-Bristol Myers merger talks, shares tumbleA report in the Financial Times, followed by Reuters, said AstraZeneca and Bristol Myers Squibb have been discussing a possible combination in recent months. The news triggered a sharp sell-off. A…